**Results:**
- Broth microdilution susceptibility testing was performed according to Clinical and Laboratory Standards Institute M07 (CLSI; 2018) reference methodology confirmed at JMI Laboratories using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry.
- The susceptibility results of representative isolates from SSSI and UTI were also confirmed by the Clinical and Laboratory Standards Institute M07-A11 (CLSI; 2018) reference methodology.
- The in vitro activity of omadacycline and comparator agents against S. aureus and S. pyogenes was compared using the same methods.
- The results of the study support the continued use of omadacycline in hospitalized patients with serious infection who may be susceptible to vancomycin.

**Acknowledgments:** This study and poster presentation were funded by a research grant from Parx Pharmaceuticals, Inc.

**References:**

**Contact Information:**
- Michael D. Huband, Michael A. Pfister, Jeremiah M. Street, Leonard R. Duncan, Robert K. Flamm
- JMI Laboratories, North Liberty, Iowa, USA.